Evidence map›Paper›PMID 19898928›Full record

ArticleJournal of clinical immunology2010

BAK, BAX, and NBK/BIK proapoptotic gene alterations in Iranian patients with ataxia telangiectasia.

Anna Isaian, Natalia V Bogdanova, Masoud Houshmand, Masoud Movahadi, Asghar Aghamohammadi, Asghar Agamohammadi, Nima Rezaei, Lida Atarod, Mahnaz Sadeghi-Shabestari, Seyed Hasan Tonekaboni and 8 more

Erratum issuedAbstract read
PubMed Publisher
In one paragraph

Article in Journal of clinical immunology, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 3 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed, 1 pooled it
0.3field-weighted citation impact, top 41% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 1 synthesis or guideline pooled it, 6 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. History of primary immunodeficiency diseases in iran.Iranian journal of pediatrics · 2010
    Article
4 · The record

Corrections and comments

  • Erratum issued
    Agamohammadi, Asghar [corrected to Aghamohammadi, Asghar]
5 · Who and what money

Authors and funding

18 authors at 6 institutions in 2 countries.

Anna IsaianNational Institute of Genetic Engineering and Biotechnology, Tehran, Iran. isaiian@sina.tums.ac.ir
Natalia V Bogdanova
Masoud Houshmand
Masoud Movahadi
Asghar Aghamohammadi
Asghar Agamohammadi
Nima Rezaei
Lida Atarod
Mahnaz Sadeghi-Shabestari
Seyed Hasan Tonekaboni
Zahra Chavoshzadeh
Seyed Mohammad Seyed Hassani
Reza Mirfakhrai
Taher Cheraghi
Najmoddin Kalantari
Mitra Ataei
Thilo Dork-Bousset
Mohammad Hossein Sanati
National Institute of Genetic Engineering and Biotechnology · IRTehran University of Medical Sciences · IRChildren's Medical Center · IRMedizinische Hochschule Hannover · DEMofid University · IRTabriz University of Medical Sciences · IR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionAtaxia telangiectasia (AT) is an autosomal recessive multisystem disorder characterized by variable immunodeficiency, progressive neurodegeneration, occulocutaneous telangiectasia, and an increased susceptibility to malignancies. This study was designed to study the role of proapoptotic BAK, BAX, and NBK/BIK genes in a group of patients with AT to elucidate the possible role of these genes in progression of malignancies in this disease. MATERIALS AND

methodsFifty Iranian patients with AT were investigated in this study. The entire coding regions of the BAK gene (exons 2-6), NBK/BIK gene (exons 2-5), and BAX gene (exons 1-7) were amplified using polymerase chain reaction (PCR). The PCR products were separated by 2% agarose gel electrophoresis, and all positive samples were verified by direct sequencing of PCR products using the same primers used for PCR amplification, BigDye chemistry, and Avent 3100 Genetic Analyzer following the manufacturer's instructions (Applied Biosystems).

resultsEight of fifty Iranian AT patients (16%) exhibited a C > T transition in exon 2 (c342C > T) of the BAK gene, while none of the healthy controls had such alteration (P = 0.0001). Higher frequency of another nucleotide substitution in the noncoding region of exon 7 in BAX gene (6855G > A) was also identified in 68% of the patient group versus 24% in the controls (P < 0.0001). Sequence alteration in intronic region of the NBK/BIK gene IVS4-12delTC was observed in 52% of AT patients, which was significantly higher than 20% in the control group (P = 0.0023). Another variant IVS1146C > T in the intronic region of the BAX gene was found in 78% of patients, which was significantly higher than 10% in the controls (P < 0.0001). Frequency of alteration in intronic region of exon 3 of the BAX gene (IVS3 + 14A > G) was also significantly higher in the AT patients (P < 0.0001). DISCUSSION: Several alterations in the proapoptotic genes BAK, NBK/BIK, and BAX were found in our study, which could elucidate involvement of the mitochondrial pathway mediated apoptosis in accelerating and developing of cancers and in immunopathogenesis of AT. Such altered apoptosis in AT could play some roles in developing cancers in this group of patients.

Indexed as

AdolescentApoptosisApoptosis Regulatory ProteinsAtaxia Telangiectasiabcl-2-Associated X Proteinbcl-2 Homologous Antagonist-Killer ProteinChildDisease ProgressionDNA Mutational AnalysisExonsFemaleGene FrequencyGenetic Predisposition to DiseaseHumansInteinsIranApoptosis Regulatory ProteinsBAK1 protein, humanbcl-2-Associated X Proteinbcl-2 Homologous Antagonist-Killer ProteinBIK protein, humanMembrane ProteinsMitochondrial Proteins

Identifiers

PMID19898928
OpenAlexW2024980845

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.